Condition-Specific Health
Ribupatide Phase Data Surfaces at ADA 2026 via Hengrui-Kailera
As the metabolic health ingredient space watches GLP-1 mimetic botanicals gain shelf space, pharma-grade peptide data c…
Condition-Specific Health 103 stories
Condition-Specific Health
Icovamenib Posts HbA1c, C-Peptide Gains in Type 1 Diabetes Trial
Biomea Fusion also flags muscle-preservation and fat-reduction signals, positioning the menin inhibitor as a potential …
Condition-Specific Health
Memocept Nootropic Stack Faces Customer Complaints and Efficacy Scrutiny
The episode underscores persistent industry pressure to back cognitive structure-function claims with peer-reviewed cli…
Condition-Specific Health
Rivus Pharma's Oral GLP-1 Candidate Shows Muscle-Preserving Effects in Preclinical Data
As GLP-1 weight-loss agents reshape the metabolic health market, lean-mass retention emerges as a key functional differ…
Condition-Specific Health
CogniHoney's Cognitive Claims Face Scrutiny Amid Safety Questions
As honey-matrix delivery formats gain shelf space in the nootropic category, regulators and consumers alike are pressin…
Condition-Specific Health
Teva AUSTEDO Data Shows QoL Gains in Huntington's Chorea
Findings from the first decentralized, real-world HD chorea study surface patient- and caregiver-reported outcomes — a …
Condition-Specific Health
Oliv18 Olive Polyphenol Supplement Targets Cardio, Antioxidant Markets
Olive polyphenols are gaining formulation traction as dual-certification positioning signals cleaner-label credibility …
Condition-Specific Health
Anti-TLR4 Monoclonal Antibody Shows Promise in Acute Kidney Injury
TLR4 pathway modulation is drawing renewed attention as a therapeutic target in immuno-inflammatory conditions — with i…
Condition-Specific Health
IV Ketamine Outperforms Nasal Esketamine in Real-World MDD Data
Yale and Osmind researchers bring peer-reviewed real-world data to the ketamine therapy debate, with implications for c…
Condition-Specific Health
CREXONT Levodopa Data: What Formulators Should Know
Extended-release carbidopa/levodopa advances in Phase 4 — a signal for the broader controlled-release delivery science …
Condition-Specific Health
Lomitapide EU Approval Expands to Pediatric Rare Lipid Disorder
The EC label expansion targets an ultra-rare genetic LDL disorder — a reminder of how orphan-drug pipelines intersect w…
Condition-Specific Health
Orelabrutinib BTK Inhibitor Posts Safety Data in SLE Phase IIb
Data presented at EULAR 2026 add to the growing clinical record for targeted immunology compounds with potential nutrac…